Stock Track | SIMCERE PHARMA Soars 5.32% in Pre-market Following Strong H1 Results and Share Buyback Plan

Stock Track

Aug 22, 2025

SIMCERE PHARMA (02096) saw its stock price surge 5.32% in pre-market trading on Friday, following the release of impressive half-year results and the announcement of a share repurchase program. The pharmaceutical company's strong performance and shareholder-friendly move have sparked investor enthusiasm.

The company reported robust financial results for the first half of 2025, with revenue reaching RMB 3.585 billion, representing a significant year-on-year increase of 15.14%. Net profit climbed to RMB 604 million, marking a substantial 32.2% rise compared to the same period last year. Basic earnings per share stood at RMB 0.25. Notably, the company's adjusted profit attributable to equity shareholders rose by 21.1% to RMB 651 million, up from RMB 538 million in the previous year.

Adding to the positive sentiment, SIMCERE PHARMA's board has resolved to implement a share repurchase program of up to RMB 500 million. This move is likely viewed favorably by investors, as it demonstrates the company's confidence in its future prospects and commitment to enhancing shareholder value. The combination of strong financial performance and the share buyback announcement appears to be driving the stock's pre-market rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1175073811"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1175073811\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1175073811?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-22 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175073811","market":"sg","top_or_hot":-1,"title":"Stock Track | SIMCERE PHARMA Soars 5.32% in Pre-market Following Strong H1 Results and Share Buyback Plan","media":"Stock Track","content":"<p>SIMCERE PHARMA (02096) saw its stock price surge 5.32% in pre-market trading on Friday, following the release of impressive half-year results and the announcement of a share repurchase program. The pharmaceutical company's strong performance and shareholder-friendly move have sparked investor enthusiasm.</p>\n\n<p>The company reported robust financial results for the first half of 2025, with revenue reaching RMB 3.585 billion, representing a significant year-on-year increase of 15.14%. Net profit climbed to RMB 604 million, marking a substantial 32.2% rise compared to the same period last year. Basic earnings per share stood at RMB 0.25. Notably, the company's adjusted profit attributable to equity shareholders rose by 21.1% to RMB 651 million, up from RMB 538 million in the previous year.</p>\n\n<p>Adding to the positive sentiment, SIMCERE PHARMA's board has resolved to implement a share repurchase program of up to RMB 500 million. This move is likely viewed favorably by investors, as it demonstrates the company's confidence in its future prospects and commitment to enhancing shareholder value. The combination of strong financial performance and the share buyback announcement appears to be driving the stock's pre-market rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SIMCERE PHARMA Soars 5.32% in Pre-market Following Strong H1 Results and Share Buyback Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SIMCERE PHARMA Soars 5.32% in Pre-market Following Strong H1 Results and Share Buyback Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-22 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SIMCERE PHARMA (02096) saw its stock price surge 5.32% in pre-market trading on Friday, following the release of impressive half-year results and the announcement of a share repurchase program. The pharmaceutical company's strong performance and shareholder-friendly move have sparked investor enthusiasm.</p>\n\n<p>The company reported robust financial results for the first half of 2025, with revenue reaching RMB 3.585 billion, representing a significant year-on-year increase of 15.14%. Net profit climbed to RMB 604 million, marking a substantial 32.2% rise compared to the same period last year. Basic earnings per share stood at RMB 0.25. Notably, the company's adjusted profit attributable to equity shareholders rose by 21.1% to RMB 651 million, up from RMB 538 million in the previous year.</p>\n\n<p>Adding to the positive sentiment, SIMCERE PHARMA's board has resolved to implement a share repurchase program of up to RMB 500 million. This move is likely viewed favorably by investors, as it demonstrates the company's confidence in its future prospects and commitment to enhancing shareholder value. The combination of strong financial performance and the share buyback announcement appears to be driving the stock's pre-market rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"","article_id":"1175073811","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175073811","pubTimestamp":1755826387,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SIMCERE PHARMA (02096) saw its stock price surge 5.32% in pre-market trading on Friday, following the release of impressive half-year results and the announcement of a share repurchase program. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02096":"先声药业"},"translate_title":"个股追踪|上半年业绩强劲及股票回购计划后先声药业盘前大涨5.32%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"SIMCERE PHARMA (02096) saw its stock price surge 5.32% in pre-market trading on Friday, following the release of impressive half-year results and the announcement of a share repurchase program. The pharmaceutical company's strong performance and shareholder-friendly move have sparked investor enthusiasm.\nThe company reported robust financial results for the first half of 2025, with revenue reaching RMB 3.585 billion, representing a significant year-on-year increase of 15.14%. Net profit climbed to RMB 604 million, marking a substantial 32.2% rise compared to the same period last year. Basic earnings per share stood at RMB 0.25. Notably, the company's adjusted profit attributable to equity shareholders rose by 21.1% to RMB 651 million, up from RMB 538 million in the previous year.\nAdding to the positive sentiment, SIMCERE PHARMA's board has resolved to implement a share repurchase program of up to RMB 500 million. This move is likely viewed favorably by investors, as it demonstrates the company's confidence in its future prospects and commitment to enhancing shareholder value. The combination of strong financial performance and the share buyback announcement appears to be driving the stock's pre-market rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}